Prosecution Insights
Last updated: April 19, 2026

Examiner: CORNELIUS, CLAIRE ADRIENNE

Tech Center 1600 • Art Units: 1600 1632 1671 1672

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
16
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

14.1%
§101 Eligibility
14.1%
§102 Novelty
39.1%
§103 Obviousness
28.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18031163 T-CELL VACCINE FOR SARS VIRUS Non-Final OA THE JOHNS HOPKINS UNIVERSITY
17997791 MODIFIED ADENO-ASSOCIATED VIRUS VECTORS THAT EVADE NEUTRALIZING ANTIBODIES AND USES THEREOF Non-Final OA The University of North Carolina at Chapel Hill
17928255 ADJUVANTS FOR SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS (SARS-COV) VACCINES Non-Final OA Children's Medical Center Corporation
18301542 TREATMENT OF INFLAMMATORY CONDITIONS Non-Final OA Kyoto University
18552635 DNA Encoded Nanoparticle Vaccine Against Human Papillomavirus, and Methods of Use Thereof Non-Final OA The Wistar Institute of Anatomy and Biology
18262073 Therapeutic Viral Vaccine Non-Final OA GlaxoSmithKline Biologicals SA
18493787 ONCOLYTIC VIRUS COMBINED WITH CAR T CELLS FOR ANTI-TUMOR THERAPY Non-Final OA Joint BioScinces
18546690 INFLUENZA VIRUS DEFECTIVE INTERFERING PARTICLES FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF CORONAVIRIDAE INFECTION Non-Final OA Otto-von-Guericke-Universität Magdeburg
18350357 FOAM VACCINATION OF AVIANS Non-Final OA UNIVERSITY OF DELAWARE
18030480 METHOD FOR DETECTION OF RNA OR DNA FROM BOLOGICAL SAMPLES Non-Final OA MATERIALS AND MACHINES CORPORATION OF AMERICA
18038665 METHODS OF TREATING SARS-COV-2 INFECTIONS Non-Final OA HAMAD MEDICAL CORPORATION
18037226 MULTICISTRONIC RNA VACCINES AND USES THEREOF Non-Final OA SEQIRUS INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month